Milestone Pharmaceuticals Inc - Asset Resilience Ratio
Milestone Pharmaceuticals Inc (MIST) has an Asset Resilience Ratio of 40.91% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2024)
This chart shows how Milestone Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Check Milestone Pharmaceuticals Inc PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Milestone Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Milestone Pharmaceuticals Inc stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $35.90 Million | 40.91% |
| Total Liquid Assets | $35.90 Million | 40.91% |
Asset Resilience Insights
- Very High Liquidity: Milestone Pharmaceuticals Inc maintains exceptional liquid asset reserves at 40.91% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Milestone Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Milestone Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Milestone Pharmaceuticals Inc (2017–2024)
The table below shows the annual Asset Resilience Ratio data for Milestone Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 58.78% | $44.38 Million | $75.50 Million | -10.66pp |
| 2023-12-31 | 69.45% | $52.24 Million | $75.23 Million | -7.01pp |
| 2022-12-31 | 76.46% | $56.95 Million | $74.48 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $119.85 Million | -- |
| 2020-12-31 | 46.67% | $70.00 Million | $149.97 Million | +46.64pp |
| 2018-12-31 | 0.03% | $29.00K | $88.08 Million | -58.08pp |
| 2017-12-31 | 58.11% | $16.03 Million | $27.59 Million | -- |
About Milestone Pharmaceuticals Inc
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical tria… Read more